TLR4 and neoplasm: Tumor-derived Tenascin-C facilitates immunosuppression and promotes pro-tumor (M2) macrophage phenotype via activation of macrophage toll-like receptor-4 (TLR-4) through the binding of the TNC protein C-terminal Fibrinogen-like globe (FBG) domain (66).